13 Mar 2014 --- Ingredia acquires 100% of Galactis Pharma shares, a company specializing in the valorization of bioactive peptides for the pharmaceutical industry. This company, established in 2011, has worked in close collaboration with university research laboratories and received various subsidies which highlighted its innovative character. “This acquisition is going to enable Ingredia to strengthen its position as a market leader in bioactive milk peptides by highlighting two of our recent patents”. Matthieu Arguillère – CEO Ingredia SA.
